Uncategorized

Vera moves into growing kidney disease space with FDA’s accelerated IgAN nod

Published

on

Vera Therapeutics’ atacicept, to be marketed as Trutakna, will go up against Novartis, Otsuka and possibly Vertex in the kidney disease primary IgA nephropathy after receiving an accelerated FDA approval.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version